NCI
GRANT WILL AID STUDY OF OMEGA-3 FATTY ACIDS FOR BREAST CANCER PREVENTION
A $1.28
million, four-year grant from the National Cancer Institute (NCI) will help
OSUCCC – James researchers test the ability of an omega-3 polyunsaturated fatty
acid (PUFA)-rich fish oil supplement to reduce the risk of recurrence in women
with highly aggressive subtypes of breast cancer.
Led by
principal investigator Lisa Yee, MD, associate professor of Surgical
Oncology at Ohio State and a member of the Molecular Carcinogenesis and
Chemoprevention Program at the OSUCCC – James, the team will randomize
high-risk breast cancer survivors to either a placebo-low dose or a high-dose
omega-3 PUFA capsule treatment. The researchers will use fine needle aspiration
techniques to obtain breast cells and tissue for analysis.
Their
primary aim is to determine the ability of dietary omega-3 fatty acids to
modulate breast epithelial and adipose tissue biomarkers of anti-carcinogenic
activity in women at high risk for recurrence of either ERPR(-)HER-2/neu(+) breast
cancer or ERPR(-)HER-2/neu(-) breast cancer (also known as triple
negative).
Yee says
their central hypothesis, based on preclinical studies, is that the development
of these aggressive subtypes may be thwarted by omega-3 PUFAs found in fish oil.
As noted in
the project’s abstract, “Our preclinical studies have demonstrated a strong
benefit for dietary omega-3 fatty acid-rich fish oil for inhibiting
ERPR(-)HER-/(neu(+) mammary tumors in a transgenic mouse model, showing
decreased tumor incidence, multiplicity and glandular atypia.”
A secondary
aim of the project, Yee adds, is to define the role of dietary omega-3 PUFAs in
epigenetic regulation of the inflammatory responses underlying breast cancer.
Development
of novel biomarkers of omega-3 PUFA exposure and response will enable
researchers to assess this fish oil supplement in future large-scale prevention
trials for women at risk for recurrence of ERPR(-)HER-2/neu(+) breast cancer or
triple-negative breast cancer.
Ohio
State co-investigators on the project include Saeed
Bajestani, MD; Martha Belury, PhD; Steven Clinton,
MD, PhD; Joanne Lester, PhD, CRNP; Zhongfa Liu, PhD; Kenneth
Riedl, PhD; Steven Schwartz, PhD; and Jianying Zhang, PhD.